Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation Guidelines of Care for the Management of Hidradenitis Suppurativa Supplement

Published: 14 September 2026| Version 1 | DOI: 10.17632/m3km5ksk6s.1
Contributor:
AAD Guidelines

Description

Background: Hidradenitis suppurativa affects 0.7-1.5% of the global population and substantial disability and meaningfully impairs quality of life. Objective: To provide evidence-based recommendations for the management of hidradenitis suppurativa. Methods: A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and to develop recommendations. Results: This guideline presents 37 evidence-based recommendations. Strong recommendations are made for adalimumab, bimekizumab, infliximab, secukinumab, and routine pain assessment. Conditional recommendations are made for topical clindamycin, resorcinol, and ruxolitinib; oral doxycycline, tetracycline, clindamycin and rifampin, and ertapenem; spironolactone; short-term systemic corticosteroids; upadacitinib; specific procedural interventions; tobacco cessation; supportive pain management; zinc supplementation and vitamin D repletion. Limitations: Analysis is limited to best evidence available from systematic review. Conclusions: These guidelines provide evidence-based recommendations for the management of hidradenitis suppurativa.

Files

Steps to reproduce

A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and to develop recommendations.

Institutions

Categories

Botulinum Toxin, Pain Assessment, Biologic Therapy, Vitamin D, Corticosteroid, Isotretinoin, Excision, Pain Management, Clinical Guideline, Hidradenitis Suppurativa

Licence